Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2008;39:3372-3377
Published online before print October 16, 2008, doi: 10.1161/STROKEAHA.108.514026
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/12/3372    most recent
STROKEAHA.108.514026v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murata, Y.
Right arrow Articles by Lo, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murata, Y.
Right arrow Articles by Lo, E. H.
Related Collections
Right arrow Animal models of human disease
Right arrow Acute Cerebral Hemorrhage
Right arrow Acute Cerebral Infarction
Right arrow Embolic stroke
Right arrow Other Stroke

(Stroke. 2008;39:3372.)
© 2008 American Heart Association, Inc.


Original Contributions

Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke

Yoshihiro Murata, MD; Anna Rosell, PhD; Robert H. Scannevin, PhD; Kenneth J. Rhodes, PhD; Xiaoying Wang, PhD Eng H. Lo, PhD

From the Neuroprotection Research Laboratory (Y.M., A.R., X.W., E.H.L.), Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass; and Biogen IDEC (R.H.S., K.J.R.), Cambridge, Mass.

Correspondence to Eng H. Lo, Neuroprotection Res Lab, MGH East 149-2401, Charlestown, MA 02129. E-mail Lo{at}helix.mgh.harvard.edu

Background and Purpose— Thrombolysis with tPA is the only FDA-approved therapy for acute ischemic stroke. But its widespread application remains limited by narrow treatment time windows and the related risks of cerebral hemorrhage. In this study, we ask whether minocycline can prevent tPA-associated cerebral hemorrhage and extend the reperfusion window in an experimental stroke model in rats.

Methods— Spontaneously hypertensive rats were subjected to embolic focal ischemia using homologous clots and treated with: saline at 1 hour; early tPA at 1 hour, delayed tPA at 6 hours; minocycline at 4 hours; combined minocycline at 4 hours plus tPA at 6 hours. Infarct volumes and hemorrhagic transformation were quantified at 24 hours. Gelatin zymography was used to measure blood levels of circulating matrix metalloproteinase-9 (MMP-9).

Results— Early 1-hour thrombolysis restored perfusion and reduced infarction. Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion. Combining minocycline with delayed 6-hour tPA decreased plasma MMP-9 levels, reduced infarction, and ameliorated brain hemorrhage. Blood levels of MMP-9 were also significantly correlated with volumes of infarction and hemorrhage.

Conclusion— Combination therapy with minocycline may extend tPA treatment time windows in ischemic stroke.


Key Words: cerebral ischemia • hemorrhagic transformation • edema • tPA • neuroprotection




This article has been cited by other articles:


Home page
StrokeHome page
S. K. Natarajan, K. V. Snyder, A. H. Siddiqui, C. C. Ionita, L. N. Hopkins, and E. I. Levy
Safety and Effectiveness of Endovascular Therapy After 8 Hours of Acute Ischemic Stroke Onset and Wake-Up Strokes
Stroke, October 1, 2009; 40(10): 3269 - 3274.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. S. Machado, I. Y. Sazonova, A. Kozak, D. C. Wiley, A. B. El-Remessy, A. Ergul, D. C. Hess, J. L. Waller, and S. C. Fagan
Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential
Stroke, September 1, 2009; 40(9): 3028 - 3033.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. Liu, J. Hendren, X.-J. Qin, and K. J. Liu
Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia
Stroke, July 1, 2009; 40(7): 2526 - 2531.
[Abstract] [Full Text] [PDF]